Recommendations in pediatric antiretroviral therapy

Expert Opin Pharmacother. 2007 Feb;8(2):155-66. doi: 10.1517/14656566.8.2.155.

Abstract

The pathogenesis of HIV infection and the general principles of therapy are the same for HIV-infected adults, adolescents, children and infants. However, antiretroviral treatment of HIV infection in pediatrics requires the consideration of a number of factors specific to its population, including differences in drug pharmacokinetics and the use of virologic and immunologic markers, as well as age-related adherence issues. This review summarizes the text of the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, which was updated in October 2006. The guidelines are the work of the Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, a group of the Office of AIDS Research Advisory Council of the National Institutes of Health, which reviews new data on an ongoing basis and provides regular updates to the guidelines. As these guidelines were developed for the US, they may not be applicable in other countries. This summary does not attempt to place the Working Group guidelines in the context of international guidelines, nor does it attempt to detail the use of antiretroviral medication in the prevention of perinatal transmission of HIV, such as addressing the use of zidovudine versus single-dose nevirapine.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • Child
  • Child, Preschool
  • Disease Progression
  • Drug Administration Schedule
  • Drug Resistance, Viral
  • HIV Infections / diagnosis
  • HIV Infections / drug therapy*
  • Humans
  • Infant
  • Infant, Newborn
  • Patient Compliance
  • RNA, Viral / blood

Substances

  • Anti-HIV Agents
  • RNA, Viral